Potential Mega-Deal: Sigma Healthcare has confirmed it is in preliminary talks to acquire the UK pharmacy chain Boots Group.
Sigma Healthcare, the owner of Chemist Warehouse, has confirmed it is in preliminary discussions regarding a potential acquisition of UK pharmacy chain Boots Group. Reports value the deal at more than $14 billion ($US10 billion).
In a statement to the Australian Securities Exchange (ASX) on Wednesday, Sigma noted that it continuously reviews value-creating opportunities and has engaged in preliminary discussions. The company emphasized that there is no certainty that any transaction will occur.
Key Details
- Deal Value: Reports estimate the potential acquisition value at approximately $14.2 billion.
- Boots Ownership: Private equity firm Sycamore Partners took control of Boots through its acquisition of Walgreens Boots Alliance.
- Sale Process: The Financial Times reported that Sycamore Partners has been in discussions with potential buyers, including Sigma and the Weston family, since before Easter.
- IPO Implications: If a sale proceeds, Sycamore Partners may abandon plans for an initial public offering of Boots in London.
Company Background
- Sigma Healthcare merged with Chemist Warehouse last year, creating a combined entity valued at $32 billion on the ASX.
- UK Expansion: In May, Sigma acquired a 75% stake in UK-based Greenlight Healthcare.
- Boots: The 177-year-old chain operates approximately 1,800 stores in the UK. In May, Boots appointed Alex Baldock as CEO, replacing Ornella Barra, who stepped down after nearly a decade.
- Weston Family: The Canadian family owns grocery chain Loblaws and pharmacy chain Shoppers Drug Mart.
Financial Performance
Boots' latest financial accounts for the year to August 2025 show:
- Total comparable retail sales rose nearly 6% in the UK, driven by beauty growth.
- The company launched over 50 new beauty brands during the period.
- Pharmacy sales rose 5%, with vaccinations and weight-loss treatments being the most popular paid-for services.
Market Reaction
Sigma Healthcare's shares fell 3.9% in early trading on Wednesday following the news.